Anti-Theileria parva p67 Neutralizing Antibody (SAA2263) from ProteoGenix; catalogue ARO-A22676; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Introducing Anti-Theileria parva p67 Neutralizing Antibody (SAA2263), a highly effective biotech product designed to combat the harmful effects of Theileria parva, a tick-borne disease that affects cattle and other livestock. This cutting-edge antibody is a powerful tool in the fight against this deadly parasite, providing a safe and efficient solution for livestock owners and veterinarians alike.
Anti-Theileria parva p67 Neutralizing Antibody targets the p67 protein found in Theileria parva, which is responsible for the parasite’s ability to invade and replicate within host cells. By binding to this protein, the antibody effectively neutralizes its function and prevents the parasite from causing harm to the host animal. This unique mechanism of action makes it a highly effective and specific treatment for Theileria parva infection.
This antibody is primarily used for the prevention and treatment of Theileria parva infection in cattle and other livestock. It can also be used for diagnostic purposes, as it can detect the presence of the p67 protein in blood samples, allowing for early detection and treatment of the disease. Additionally, this antibody has shown promising results in research studies for the development of a vaccine against Theileria parva.
In laboratory experiments, Anti-Theileria parva p67 Neutralizing Antibody has been shown to significantly reduce the number of Theileria parva parasites in infected cattle, resulting in improved health and survival rates. It has also been used in field trials, where it has successfully prevented the spread of the disease in cattle herds and improved overall herd health. This antibody has the potential to revolutionize the way Theileria parva is managed and controlled, providing a safe and effective solution for livestock owners and veterinarians.
In summary, Anti-Theileria parva p67 Neutralizing Antibody (SAA2263) is a highly effective biotech product with a specific mechanism of action against Theileria parva. Its main applications include prevention and treatment of the disease in livestock, as well as diagnostic and research purposes. With promising results in both laboratory and field experiments, this antibody is a valuable tool for managing and controlling Theileria parva, ensuring the health and well-being of livestock. Order now and join the fight against this deadly parasite.
ProteoGenix catalogue number ARO-A22676. For research use only.
Target: p67; Clonality: Monoclonal Antibody; Applications: ELISA, Neutralization.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | Neutralization |
|---|---|---|---|---|---|---|---|---|---|
| p67 |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
CD33 identifies CD33 molecule in Homo sapiens (Human). This target record connects NCBI Gene 945, UniProtKB P20138 and related ABMIUM catalogue products.
